- Punti reazioni
vediamo se pullbacka qualche cosa.....o se è scappata anche questa
Scritto da tremaui
frame 5 min day...se serve altro chiedi
ferme circa 428.000 pz. short al momentoScritto da ffaiper
come mi hai fato notere,su ALTI le posizioni di short si fermano a 1$,e poi riparte fino a 1,06$,per poi ritornare a 1$ per ora!!! su vion dopo il piccolo strappo in rialzo di oggi,le posizioni di short sono diminuite!?? up
CR: Vion Presents Preclinical Data on Triapine(R) at AACR Meeting [CWVTKNP]Scritto da valsente
E' da venerdi' che salta come un canguro e cammina come un gambero. Cosa ne pensate?
Vale la pena di restarci dentro a 2.19?
Scritto da tremaui
CR: Vion Presents Preclinical Data on Triapine(R) at AACR Meeting [CWVTKNP]
08:03am EDT 14-Jul-03 PR Newswire - First Call Wire (Vion Pharmaceuticals, Inc
Vion Presents Preclinical Data on Triapine(R) at AACR Meeting
NEW HAVEN, Conn., July 14 /PRNewswire-FirstCall/ -- Vion Pharmaceuticals,
Inc. (Nasdaq: VION) announced today that preclinical data of its anticancer
agent Triapine(R) in combination with Ara-C were presented in a poster session
at the 2003 American Association for Cancer Research Annual Meeting in
The experiments, performed in cancer cell lines, demonstrate that
Triapine(R) increases uptake of Ara-C in cancer cells and at the same time
increases incorporation of Ara-C into cellular DNA, which produces cell death.
The combination of low doses of Triapine(R) followed by exposure to Ara-C
resulted in either synergistic or additive cytotoxicity to cancer cell lines
Dr. Mario Sznol, Vice President, Clinical Affairs, stated, "These
preclinical data, together with similar data generated for gemcitabine,
demonstrate that Triapine(R) consistently enhances the anticancer effects of
nucleoside analogues. The recently initiated clinical trials of Triapine(R)
in combination with Ara-C in leukemia and with gemcitabine in non-small-cell
lung and pancreatic cancer will provide safety and activity information for
these combinations in humans."
Triapine(R) is designed to be a potent inhibitor of ribonucleotide
reductase, an enzyme important for DNA synthesis. Ara-C is a nucleoside
analogue that is used alone and in combination for the treatment of leukemia.
Gemcitabine is a nucleoside analogue sold under the brand name Gemzar(R) by
Eli Lilly & Company for the treatment of certain solid tumors.
Vion Pharmaceuticals, Inc. is a biopharmaceutical company developing novel
agents for the treatment of cancer. Vion's portfolio of agents includes:
Triapine(R), a potent inhibitor of a key step in DNA synthesis; VNP40101M, a
unique DNA alkylating agent; and TAPET(R), a modified Salmonella vector used
to deliver anticancer agents directly to tumors. For additional information
on Vion and its research and product development programs, visit the company's
Internet web site at www.vionpharm.com.
This news release contains forward-looking statements. Such statements are
subject to certain risk factors which may cause Vion's plans to differ or
results to vary from those expected, including Vion's ability to continue as a
going concern, which is dependent on securing external sources of funding to
continue its operations, the inability to access capital and funding on
favorable terms, continued operating losses and the inability to continue
operations as a result, its dependence on regulatory approval for its
products, delayed or unfavorable results of drug trials, the possibility that
favorable results of earlier clinical trials are not predictive of safety and
efficacy results in later clinical trials, the need for additional research
and testing, and a variety of other risks set forth from time to time in
Vion's filings with the Securities and Exchange Commission, including but not
limited to the risks discussed in Vion's Annual Report on Form 10-K for the
year ended December 31, 2002. Except in special circumstances in which a duty
to update arises under law when prior disclosure becomes materially misleading
in light of subsequent events, Vion does not intend to update any of these
forward-looking statements to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events.
Scritto da thecrow
be', anche io e' da un po' di tempo che l'ho messa a monitor
vediamo un po' se questo ha una valenza, prendetelo con le molle, sto grafico eh